New Products

STAMFORD, Conn. — The Food and Drug Administration has accepted Purdue Pharma's regulatory approval application for a new opioid drug, Purdue said Tuesday.

The drug maker announced the FDA's acceptance of its application for Targiniq (oxycodone hydrochloride; naloxone hydrochloride) controlled-release tablets. The drug combines oxycodone with the opioid agonist nalxone.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new tablet form of an antifungal drug made by Merck, the company said Tuesday.

Merck announced the FDA approval of Noxafil (posaconazole) 100-mg delayed release tablets. The company also markets a 40-mg-per-milliliter oral suspension form of the drug. The new tablet formulation is designed to be taken in two 300-mg doses on the first day, followed by a 300-mg dose once per day.

MEAD, Wash. — Movit Energy Gummies recently launched its signature product targeting active sports enthusiasts with an energy product in gummy format. 

Movit comes in a snack-size packet typically containing 11 gummies, which altogether contain 60 calories, in one of two flavors — citrus or berry. The proprietary formula includes such ingredients as Brazilian guarana, co-enzyme Q10, D-ribose, vitamin C, taurine, protein and a full complement of B vitamins.

The energy formula meets high school and NCAA guidelines, the company stated.

TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

MADISON, N.J. — Pfizer on Monday launched Robitussin Maximum Strength Cough + Congestion DM, a new liquid-filled capsule that helps control cough on-the-go. "This formulation not only harnesses the power of Maximum Strength Robitussin cough liquid, but is a convenient option for those hitting the road or boarding a plane this holiday season," the company stated.

The company noted that whether traveling cross country or staying close to home, families can track when cough activity spikes in their local area via the Robitussin COUGHCAST tool. 

PRINCETON, N.J. — Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, announced the launch of authorized generic diclofenac gel in the 3% strength. The drug is a version of PharmaDerm's Solaraze.

JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

NEW YORK — The Food and Drug Administration has granted regular approval to a new drug made by Pfizer for treating a form of lung cancer, the drug maker said.